Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma

Kazushi Numata(Yokohama City University Medical Center), Katsuaki Tanaka(Yokohama City University Medical Center), Tomohiro Ishii(Tokyo Metropolitan Children's Medical Center), Masahiro Okada, Akito Nozaki(Yokohama City University Medical Center), Masaaki Kondo(Yokohama City University Medical Center), Hiroyuki Fukuda(Yokohama City University Medical Center), Haruo Miwa(Yokohama City University Medical Center), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Masayuki Nakano(Nihon University), Shigeo Takebayashi(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Akinori Nozawa(Yokohama City University Medical Center), Satoshi Moriya(Yokohama City University Medical Center)
European Journal of Radiology
October 6, 2013
10.1016/j.ejrad.2013.09.025
Cited by 38

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333